

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows.

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (Presently amended) A cell-free composition comprising a complex ~~PKB Ser473 kinase~~, which ~~when associated with cellular proteins~~ has a-PKB Ser 473 kinase activity and has an apparent molecular weight of 450-650 kDa.

Claim 2. (Cancelled)

Claim 3. (Presently amended) The cell-free composition of claim 1, wherein said complex ~~composition~~ comprises a protein having a molecular weight of 48kDa as estimated by SDS gel electrophoresis.

Claim 4. (Presently amended) The cell-free composition of claim 1, wherein said complex ~~composition~~ comprises a protein having a molecular weight of 58kDa as estimated by SDS gel electrophoresis.

Claim 5. (Presently amended) Purified PKB Ser 473 kinase protein complex, which ~~when associated with cellular proteins~~ has a-PKB Ser 473 kinase activity and has an apparent molecular weight of 450-650 kDa when fractionated by gel filtration chromatography.

Claim 6. (Cancelled)

Claim 7. (Previously presented) A purified cell extract that has measurable PKB Ser 473 kinase activity in 0.2 µg of protein when detected in a kinase assay in which a PKB peptide substrate is phosphorylated with <sup>32</sup>P labelled phosphate, wherein the kinase elutes with an

apparent molecular weight of 450-650 kDa when fractionated by gel filtration chromatography.

Claim 8. (Previously presented) The purified cell extract of claim 7, wherein the kinase elutes with an apparent molecular weight of 550 kDa when fractionated by gel filtration chromatography.

Claim 9. (Cancelled)

Claim 10. (Withdrawn) A method for producing antibodies which selectively bind to a purified PKB Ser 473 kinase protein comprising the steps of:

- i) administering an immunogenically effective amount of a PKB Ser 473 kinase immunogen to an animal;
- ii) allowing the animal to produce antibodies to the immunogen; and
- iii) obtaining the antibodies from the animal or from a cell culture derived therefrom.

Claim 11. (Withdrawn) APKB Ser 473 kinase-specific antibody.

Claim 12. (Withdrawn) A method of screening for a potential modulator of PKB Ser 473 kinase activity comprising the steps of:

- i) incubating the purified PKB Ser 473 kinase protein of claims 5 or 6 with a compound;
- ii) determining PKB Ser 473 kinase activity;
- iii) detecting an alteration in the PKB Ser 473 kinase activity in the presence of the compound relative to when said compound is absent, said alteration being indicative of a potential modulator of PKB Ser 473 kinase activity.

Claim 13. (Withdrawn) The method according to claim 12 wherein said alteration in the PKB Ser 473 kinase activity is a decrease in PKB Ser 473 kinase activity, said decrease being indicative of a potential inhibitor of PKB Ser 473 kinase.

Claim 14. (Withdrawn) The method as claimed in claim 12 wherein said alteration in the PKB Ser 473 kinase activity is an increase in the PKB Ser 473 kinase activity said increase being indicative of a potential activator of PKB Ser 473 kinase.

Claim 15. (Withdrawn) A modulator of PKB Ser 473 kinase activity.

Claim 16. (Withdrawn) The modulator of claim 15 for use as a pharmaceutical.

Claim 17. (Withdrawn) The use of the modulator of claim 15 for the manufacture of a medicament for the treatment or prophylactic treatment of a condition associated with cell growth.

Claim 18. (Withdrawn) The use as claimed in claim 17, wherein said condition is turnout cell growth.

Claim 19. (Withdrawn) The use of the modulator of claim 15 for the manufacture of a medicament for the treatment or prophylactic treatment of diabetes, neurodegenerative conditions or erectile dysfunction, wherein said modulator is an activator.

Claim 20. (Withdrawn) A method for inhibiting cancer cell growth comprising contacting a cancerous cell with a PKB Ser 473 kinase inhibitor.

Claim 21. (Withdrawn) A method for treating a disease associated with an anomaly in cell growth comprising administering to a subject a pharmaceutically effective amount of a PKB Ser 473 kinase inhibitor.

Claim 22. (Withdrawn) A method for treating a disease associated with an anomaly in cell growth comprising administering to a subject a pharmaceutically effective amount of a PKB Ser 473 kinase inhibitor.

**Claim 23. (Withdrawn)** A method for treating a disease associated with an anomaly in insulin regulation, neurodegeneration or erectile dysfunction comprising administering +to a subject a pharmaceutically effective amount of a PKB Ser 473 kinase activator.